A comprehensive view of Shionogi & Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.
ViiV Healthcare's long-acting injectable antiretroviral treatment for HIV, Cabenuva, shows superior efficacy in maintaining viral load suppression compared to daily oral therapy; results come from interim results from Phase 3 trial
Published:
February 21, 2024
by GSK Group (GlaxoSmithKline)
|
China approves ViiV Healthcare's injectable HIV treatment consisting of Vocabria cabotegravir and Janssen's Rekambys rilpivirine; HIV affects over 1 million people in China
Published:
October 27, 2023
by Targeted News Service (Press Releases)
|
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at 19th Annual European AIDS Conference in Warsaw, Poland from October 18-21
Published:
October 18, 2023
by M2 PressWIRE
|
European Medicines Agency gives positive opinion for marketing authorization of ViiV Healthcare's cabotegravir, an injectable and tablet for HIV prevention; ViiV Healthcare is owned by GSK as a majority shareholder, along with Pfizer and Shionogi & Co
Published:
July 24, 2023
by Alliance News
|
Ask us about our Consumer Wellness market view